Introduction
Achievement of sustainable transgene expression in vivo by non-viral transfer approach is a major goal in current gene therapy research. The magnitude of transgene expression mainly depends upon the promoter activity, thus strong promoters such as CMV (1) or CAG (2) have been preferentially used in the study pursuing in vivo transgene expression. In fact, these promoters attain strong expression of a transgene shortly after DNA delivery, but this expression rapidly dissipates within several weeks (3) (4) (5) (6) (7) (8) . A potential mechanism behind this downregulation is immune-mediated elimination of the cells bearing exogenous gene products (5, (7) (8) (9) .
This may raise a significant concern when considering gene therapy for humans, since proteins responsible for congenital deficiencies are often recognized as foreign by the patient's immune system. It is reported that enzyme replacement therapy induces an immune response to deficient proteins in patients with a wide range of congenital deficiencies such as hemophilia A and B (10) , adenosine deaminase deficiency (11) , mucopolysaccharidosis type I (12), Gaucher disease (13) , Fabry disease (14) , and Pompe disease (15) . Hence, regulation of the host immune system is a key for successful gene therapy targeting congenital protein deficiencies. An attractive approach avoiding elicitation of the immune response against a gene product is the use of a target tissue-specific promoter that is generally inert in antigen presenting cells. A number of tissue-specific promoters have been tested in various models (16, 17) , however, these promoters are too weak to induce target gene expression at a therapeutic level. Accordingly, it is of importance to establish a strategy that can induce robust transgene expression but not elicit immune response against a transgene product. In the present study, we sought to establish a novel transcriptional control system that attained potent and sustainable exogenous gene expression in vivo.
Tandem repeats of an NF-κB or AP-1 binding element were introduced into the CMV promoter which drives the target gene, and then NF-κB or AP-1 was provided by cisexisting expression cassette. This system, designated as the transcription factor (TF)-supercharging promoter system, allowed creation of a transcriptional feedback circuit by cisacting elements within the promoter and corresponding transacting factors expressed exogenously, which drives mandatory expression of a transgene. Our results demonstrated that the AP-1-mediated supercharging promoter system can attain enhanced and prolonged xenogeneic human SEAP expression in mice while the conventional vector failed to sustain the expression. This system may be well suited for applications where high-level and long-lasting therapeutic gene expression is required, especially in patients who may develop an immune response to a therapeutic protein during enzyme replacement therapy.
Materials and methods
Plasmid vectors. The parental vector used in plasmid construction is pGA (18) that consists of CMV promoter plus intron A, bovine growth hormon terminator, Kanr, and pUC backbone. Fig. 2 shows a schematic illustration of the supercharging promoter characterized in the current study. Unique restriction sites were created in the CMV promoter using a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) to allow insertion of a transcriptional activator binding element ( Fig. 2A) . Tandem repeats of transcription factor (TF) binding motif, five tandem repeats of the κB element (K motif) or seven tandem repeats of the 12-Otetradecanolyphorbol 13 acetate-responsive element (T motif) were from PathDetect in vivo cis-reporting system (Stratagene). Each motif was amplified by PCR and digested with the corresponding restriction enzymes, and then ligated into an appropriate region of the CMV promoter as illustrated in Fig. 2B and 2C. Reporter genes, firefly luciferase (luc) and human secretory alkaline phosphatase (huSEAP) were subcloned from pGL3 control (Promega, Madison, WI) and pSEAP2-control (BD Clontech, Palo Alto, CA), respectively. LacZ and chloramphenicol acetyl transferase (CAT) used as a mock insert were obtained from pSV-ß-galactosidase and pCAT3-basic (both from Promega), respectively. Mouse SEAP (muSEAP) was cloned from C2C12 murine myoblast as reported by Wang et al (19) . Mouse RelA, cFos, and cJun were cloned from mouse spleen cDNA library as described elsewhere (20) . Dual or triple promoter vectors were constructed by ligation of two or three expression cassettes in tandem as described previously (21) .
Transfection and luciferase assay. The cell lines used in this study are listed in Table I . Each cell line (cultured in DMEM high-glucose supplemented with 10% FCS) was seeded in a 96-well tissue culture plate and grown until reaching 50-70% confluency. Then cells were transiently transfected using FuGene 6 (Roche, Mannheim, Germany) in triplicate. Each transfection mixture contained different dose combinations of reporter, transcription activator, and mock plasmid. Two days following transfection, the luminescence signal was measured by a microplate luminescence reader (Fluostar, BMG Labtechnologies, Duren, Germany) with a Bright-Glo kit (Promega) according to the manufacturer's instruction. A secondary reporter (ex. Renilla luciferase) for standardization of primary reporter activity was not employed in this work, since we found that commonly used promoters (ex. CMV, CAG, SV40, and HSV-TK) were susceptible to cotransfected TF plasmid. Therefore any secondary reporters seemed not to serve as an internal control, and we intended to eliminate experimental variations by repeating experiments.
Animal treatment and measurement of plasma SEAP activity.
Male BALB/c and SCID mice were purchased from Japan Clea and housed in the animal facility of the Leprosy Research Center, National Institute of Infectious Diseases or Yokohama City University Graduate School of Medicine. DNA injection, electroporation, and retro-orbital puncture for blood sampling were all performed under anesthesia by subcutaneous injection of the 4:1 mixture of Ketamine and Xylazine. Animal experiments were conducted under the approval of the institutional laboratory animal care and use committee. In electroporation, the quadriceps femoris muscle was exposed and injected with the indicated dose of plasmid in saline with a 30-gauge needle inserted 2-3 mm deep, then the entire muscle bundle was pinched by a pair of disk-type platinum electrodes (diameter: 10 mm, separation: ~5 mm, CUY650-10; Nepa Gene, Chiba, Japan). Six electrical pulses were applied at 30 V by a square wave electroporator CUY21EDIT (Nepa Gene), with pulse duration of 50 ms, pulse interval of 100 ms, and reversal of polarity after three pulses, followed by the closure of incision with surgical wound clips. Scheduled blood samples were taken by retro-orbital punctuation and stored at -20˚C until assayed. Plasma SEAP activity was measured using an SEAP reporter gene chemiluminescent assay kit (Roche) using a microplate luminescence reader according to the manufacturer's instruction.
RNA extraction and real-time PCR.
To explore the transgene expression pattern in muscle and lymphoid tissue by different transcriptional control, transgene expression was quantified by real-time RT-PCR at the messenger RNA level. To eliminate immune-mediated loss of transgene expression, mouse SEAP was used in this experiment. One or three days following electroporation-mediated DNA delivery, mice were sacrificed and the inguinal lymph nodes and muscles were harvested. RNA was extracted with TRIzol reagent (Invitrogen, Life 
Technologies, Carlsbad, CA) in accordance with the manufacturer's instructions. Before cDNA synthesis, each RNA sample was treated with DNase I (Invitrogen Life Technologies) to eliminate any potential contamination with plasmid or genomic DNA. Reverse transcription was performed with 2 μg of total RNA using a superscript II reverse transcription amplification system (Life technologies, Invitrogen) with random hexamers. Real-time PCR amplification was performed on an ABI PRISM 7700 using SYBRGreen dye. PCR conditions were 50˚C for 2 min, 95˚C for 10 min, then 40 cycles at 95˚C for 15 sec, and 60˚C for 1 min. The primer set 5'-ATG TGG GGA GCC TGC TTG CTG-3' (forward) and 5'-CCA GAT GGC CTT GCT GCT GCC-3' (reverse) was used to amplify a 244-bp fragment of the mouse SEAP mRNA gene. For quantitative evaluation of gene expression, mouse SEAP mRNA levels were normalized to the 18S-mRNA as suggested by Applied Biosystems.
Statistics. Statistical analysis was conducted with one-way analysis of variance (ANOVA) or paired t-test using StatView J-4.02 software (Abacus Concepts, Berkeley, CA), and significance was defined when p<0.05.
Results
Strategy for transcriptional control. The principle for the supercharging promoter system is shown in Fig. 1 . In the conventional expression system, a single promoter drives the transcription of a target gene (Fig. 1A) . To ameliorate the promoter activity of current gene therapy vectors, we sought to establish a novel system that would allow mandatory expression of a transgene as shown in Fig. 1B . A transcription factor binding motif (enhancer site) was introduced into the CMV promoter, then a corresponding transcription factor was supplied by cis-existing expression cassette. This was expected to induce robust transgene expression by the action of positive-feedback circuit composed of cis-(enhancer sites) and trans-(TFs) acting elements. To test the principle of this strategy, the promoters CMV-K, CMV-KK, CMV-KKK, CMV-T, CMV-TT, and CMV-TTT were constructed by introducing K or T motif into their CMV promoter regions as illustrated in Fig. 2B and C. NF-κB is a pivotal transcriptional regulator in controlling innate and adaptive immunity (22) while AP-1 regulates genes involved in cell growth (23) . Among several TF candidates for each TF-binding site, we used RelA (p65) for K motif and c-Fos and c-Jun heterodimer for T motif, since these combinations demonstrated a potent trans-activity in preliminary in vitro experiments (data not shown).
Transgene expression by the supercharging promoter system in vitro. To determine if this approach is capable of ameliorating transgene expression performance, HEK293 and NIH-3T3 cells were transiently cotransfected with a reporter and corresponding TF expression plasmid(s) (equimolar cFos and cJun plasmids were applied for AP-1). As shown in Fig. 3A , luc expression in HEK 293 cells increased in accordance with increasing the number of K motifs in a promoter, whereas these promoters showed a marginal effect in NIH-3T3 cells. In contrast, introduction of T motifs successfully augmented luc expression in both cell lines (Fig. 3B ). These results suggest that the effect of co-expressed TF may depend on cell type. We also sought to determine how many copies of K or T motifs were optimal for the postive-feedback effect. No statistical differences were noted in the expression level between CMV-KKK and -KK or between CMV-TTT and -TT. Simultaneously, significant differences were found between CMV-KK and -K in HEK 293 cells and CMV-TT and -T in both cells, indicating that two copies of K or T motifs might be sufficient. To verify if this observation is consistent across cell lines, the same experiments were conducted using C2C12, C6, HeLa, HepG2, and ST2 cells, which gave similar results (data not shown). These results suggest that two or three copies of K or T motifs are optimal for the system. Accordingly, CMV-KKK and CMV-TTT promoters were used in further experiments to determine the dose-response relationship between the amount of cotransfected TF plasmid and the activity of the chimeric promoter. Table II . Evaluation of an NF-κB and AP-1-mediated supercharging promoter system in various cell lines. 
The cells were transiently transfected with the indicated plasmids, and firefly luciferase activities were measured 2 days following transfection. Values were standardized individually for each cell line by using the negative control group (CMV/luc + CMV/LacZ) to provide a basis for comparison among groups. The experiments were repeated at least three times with similar results. The data shown are averages of triplicated measurements ± standard errors. a Significant difference between the naive and the supercharging promoter in the presence of an appropriate transcription activator plasmid. Fig. 3C shows luc expression by the CMV-KKK promoter in the presence of various doses of RelA plasmid. In HEK 293 cells, a linear increase of luc activity was found with increasing doses of RelA plasmid, and a 70-fold enhancement was seen at the dose of 40 ng/well. When NIH-3T3 cells were tested, luc expression increased in a dose-dependent manner, plateauing at 20 ng/well, which was 30-fold over the control. AP-1 (equimolar c-Fos and c-Jun) plasmid also accelerated the luc expression by the CMV-TTT promoter (Fig. 3D) . Again, HEK 293 cells showed a linear increase of luc activity corresponding to an increase of cotransfected AP-1. However, in NIH-3T3 cells, luc activity reached a peak that was <30-fold over the control. These observations suggested that doseresponse kinetics depends upon the nature of the cell lines.
To further characterize the action of the supercharging promoter system, similar experiments were repeated with various cell lines (Table II) . It was again noteworthy that the system performance depended on the type of cell line, suggesting that i) compatibility of cis-and trans-acting factors for gene expression machinery of the individual cell type and ii) endogenous cofactor(s) determine the magnitude of resultant transgene expression. The combination of the CMV-KKK promoter and RelA showed a robust expression in C6 and a moderate effect in HeLa, HepG2, A431, and C2C12 cells, while that of the CMV-TTT promoter and Ap-1 demonstrated a good performance in ST-2, C6, and C2C12 cells. No enhancement was observed with any of these promoters in CHO-K1 cells. However, the substantial effect seen in C2C12 myoblast inspired us to apply the strategy in vivo, since the muscle is a major target for in vivo gene transfer.
Transgene expression by the supercharging promoter system in vivo. We next examined whether the TF-supercharging promoter system can improve the magnitude and longevity of xenogeneic protein expression in mouse muscle. Human placental secretory alkaline phosphatase (huSEAP) that has immunogenicity in mice was employed as a reporter gene. SEAP activity was monitored by a plasma-based assay that allowed long-term surveillance of gene expression profile without sacrificing animals. It is an essential requirement for the system that reporter and TF plasmid is coexistent in individual cells. Two independent plasmids can be transferred into an individual cell by conventional transfection reagents in vitro, however, co-transfection with two plasmids into a single cell is unlikely in vivo. To pursue a maximal effect of the system in vivo, we constructed plasmids that carry both a Figure 3 . The supercharging promoter system accelerates the transgene expression in HEK293 and NIH-3T3 cells. CMV promoters containing one to three copies of the K motif (A) or T motif (B) were examined for their ability to enhance luc expression in the presence of the corresponding transcriptional activator plasmid (Rel A for the K motif, AP-1 for the T motif). The cells were cotransfected with a reporter (10 ng/well) and a transcription activator plasmid(s) (50 ng/well, for AP-1, equimolar amount of c-Fos and c-Jun plasmid), and luc activity was measured 2 days following transfection. The transcription factor dose-dependent luc expression kinetics controlled by the CMV-KKK (C) and CMV-TTT (D) promoters were also analysed 2 days following transfection. The dose of the transcription activator plasmid was increased from 0 to 40 ng/well, while the dose of the reporter plasmid was maintained at 1 ng/well. To make the transfected DNA amount constant, 40 to 0 ng/well of the mock plasmid (CMV/LacZ) was also contransfected. All values were standardized individually for each cell line using an appropriate negative control to provide a basis for comparison. The data shown are averages of triplicated measurements, and error bars indicate the standard deviations. The experiments were repeated twice with similar results.
reporter and TF gene in a single backbone by using a multiple promoter vector (21) (Fig. 4A ). For AP-1, a triple promoter vector was constructed to express SEAP and c-Fos/c-Jun heterodimer simultaneously. Then quadriceps femoris muscle was transfected with this huSEAP expression plasmid by electroporation and SEAP activities were monitored consecutively for 10 months (Fig. 4B) . The tricistronic vector that carries CMV-TTT promoter-driven SEAP and wild-type promoter-driven c-Fos and c-Jun sustained high-level SEAP expression throughout the observation period. Bicistronic vector that carried CMV-KKK/SEAP and CMV/RelA showed neither enhanced nor prolonged huSEAP expression (observation was truncated at day 56), exhibiting a striking difference of the system performance between in vitro and in vivo. A conventional huSEAP expression vector, in which the huSEAP gene is regulated by naïve CMV promoter, reached a peak close to the level obtained by the tricistronic vector, but plasma SEAP activity decreased rapidly and then sunk below the detection limit. The size-matched control for the tricistronic vector, which comprised of naïve CMV promoterdriven huSEAP and two copies of chloramphenicol acetyl transferase expression cassette, showed an expression profile that is similar to the conventional huSEAP expression vector. Thus, our novel approach is validated as useful in pursuing high and long-lasting expression of huSEAP in mice.
To clarify the relationship between performance of the AP-1-mediated supercharging promoter system and immunogenicity of a transgene, xenogeneic huSEAP was replaced with allogeneic muSEAP, and then SEAP expression profiles were monitored consecutively (Fig. 4C) . A marked difference was observed regarding the longevity of SEAP expression depending upon the origin of SEAP. All three vectors used in the muSEAP experiment showed a sustained expression. It is noteworthy that the level of SEAP expression by a conventional plasmid was higher than that by the vector installed with AP-1-mediated supercharging promoter throughout the observation period. However, the vector installed with AP-1-mediated supercharging promoter exhibited a higher level of SEAP expression than the tricistronic vector that has no supercharging promoter system, this difference might be explained by transactivation of CMV-TTT promoter by AP-1. The reason for the stronger muSEAP expression by the conventional promoter than by the supercharging promoter might be the plasmid size, as it is likely that the conventional muSEAP vector (5.4 kb) enters into a cell more efficiently than the AP-1-mediated supercharging promoter vector (12 kb). The above results suggest that the system may be suited for gene therapy targeting congenital protein deficiencies in which a patient develops an immune response against a therapeutic protein during enzyme replacement therapy.
Verification of immune-mediated clearance of huSEAP expression in vivo.
To examine whether the clearance of huSEAP is attributed to an immune-mediated mechanism, huSEAP expression by a naïve CMV promoter was compared between immunocompetent and immunodeficient mice (Fig. 5) . The mice (8 mice/group) were transfected with 50 μg of each plasmid by intramuscular electrotransfer at day 0, and plasma SEAP activity was monitored continuously. Plasma from eight mice in each group was assayed. The data shown are averages of triplicated measurements and the standard deviations. * Significant difference between two groups at the specific time point (p<0.05). An independent experiment showed a similar result.
As expected, in immunodeficient SCID mice, no loss of plasma SEAP activity was observed. Expression from 100 μg of CMV/huSEAP was much higher than that from 10 μg of the same plasmid, i.e. dose-dependent huSEAP activity is preserved. In contrast, in immunocompetent BALB/c mice, SEAP expression from 100 μg of CMV/huSEAP was initially higher than that from 10 μg of CMV/huSEAP, however, expression from 100 μg of the vector had fallen dramatically to almost basal level within 28 days. This suggests that stronger transgene expression elicits a stronger immune response to a gene product, which interferes with later transgene expression. We therefore verified that huSEAP clearance occurred by an immune-mediated mechanism. Accordingly, it is proved that the AP-1-mediated supercharging promoter system maintains huSEAP expression against the immune-mediated clearance, further suggesting that the system fulfilled long-lasting gene expression not only by improving transcriptional activity but also by induction of immunological tolerance to huSEAP.
Comparison of mRNA expression level by conventional and AP-1-mediated supercharging promoter.
To elucidate the mechanism underlying the induction of immunological tolerance to a xenogeneic gene achieved by AP-1-mediated supercharging promoter, transgene expression by conventional and supercharging promoter was analyzed in the lymph nodes and muscle at the messenger RNA level. In this experiment, non-immunogenic mouse SEAP is chosen as a reporter, since its expression is not subject to immune-mediated clearance and can reflect the net effect of transcriptional performance. As Table III shows, it is obvious that the standard CMV promoter can achieve higher mRNA expression than the supercharging promoter system not only in the lymph nodes but also in the muscles. At day 1, the supercharging promoter showed a significantly lower mRNA expression than the conventional promoter in the lymph nodes, which could be responsible for the induction of immunological tolerance to a transgene. A markedly different transgene mRNA expression seen in the muscle might also play a role in determining whether a transgene product is recognized or passed over by the host immune system.
Discussion
The present report describes initial results from experiments in which our supercharging promoter system tested whether this strategy can ameliorate transgene expression in cell cultures and in mice. A major achievement in this study is the establishment of a strategy that is capable of sustaining high-level transgene expression following electroporationmediated plasmid transfer into the muscle. In the attempt to seek effective gene therapy using plasmid vectors, the muscle has been a major target because it is easily accessible and efficiently secretes the transgene product into the systemic circulation (24) . Thus, amelioration of gene expression in the muscle might contribute to the progress of gene therapy targeting congenital disorders that can be treated with a therapeutic gene product in the circulation, i.e. hemophilia (25) and lysosomal storage diseases (26) . In fact, previous studies have shown that intramuscular plasmid injection results in the production of therapeutic protein in hemophilia (3) and lysosomal storage diseases (6) . However, the lack of persistent gene expression hampers efforts to supply therapeutic levels of target gene products. In this regard, our system might be suited for gene therapy targeting disorders that can be treated by supplying a deficient protein in the systemic circulation. Another concern in designing a gene therapy strategy targeting these congenital disorders is elicitation of immune responses to a deficient protein, as the patient's immune system might recognize a previously unexpressed protein as foreign. In fact, production of the antibody against deficient proteins has been reported in patients under enzyme replacement therapy for various congenital deficiencies such as hemophilia A and B (10), adenosine deaminase deficiency (11), mucopolysaccharidosis type I (12), Gaucher disease (13), Fabry disease (14), and Pompe disease (15) . In these patients, antibodies may neutralize --------------------------------------------- ----Mice were transfected with the plasmid expressing mouse SEAP under the indicated transcriptional control by electroporation, and the injected muscle and inguinal lymph nodes were harvested at day 1 and 3. Mouse SEAP mRNA was quantified by real-time PCR after RNA extraction and reverse transcription. The data shown are mean of five animals ± standard errors. A repeated experiment showed a similar result. a Significant difference between the naïve CMV and CMV-TTT group at the same time point.
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the bioactivity of the therapeutic protein, moreover, administration of the vector encoding therapeutic protein might augment an immune response to a transgene as seen in primeboost immunization of DNA vaccines. huSEAP is xenogeneic protein to mice and able to mimic a therapeutic gene product in a patient with congenital protein deficiency, as it has both bioactivity and immunogenicity in mice (5, 8) . Hence, emphasis is given to the long-lasting expression of the huSEAP gene achieved by the TF-supercharging promoter consisting of CMV-TTT and AP-1, again providing favorable characteristics for gene therapy targeting congenital protein deficiencies, especially for patients who develop an immune response against a deficient protein. Following up the current study, the expression profile of therapeutic, but not reporter genes should be analysed using the CMV-TTT promoter and AP-1 to determine whether the system can exert its performance in a gene therapy model.
When allogeneic muSEAP was used as a reporter, SEAP expression persisted for more than 100 days regardless of the transcriptional control. This is in marked contrast to the rapid decrease of the transgene expression observed in huSEAPtreated animals. As noted, the strongest SEAP expression was attained by the conventional but not TF-supercharging promoter, presumably owing to the small plasmid size that is preferred for cellular uptake of plasmids. The AP-1-mediated supercharging promoter may therefore provide little help for improving transgene expression as long as a non-immunogenic gene is used. However, several studies of allogeneic factor VIII (27) (28) (29) (30) , IX (31, 32) , and erythropoietin (33,34) gene transfer into animals indicate the risk of eliciting immune responses against a transgene, even if it originates from the same species. Thus we believe that the AP-1-mediated supercharging promoter system might confer considerable benefit for gene therapy targeting congenital protein deficiencies in which the therapeutic gene is recognized as foreign by the patient's immune system. The huSEAP expression profile observed in immunocompetent and immunodeficient mice displayed a striking contrast, decreasing huSEAP expression was seen only in immunocompetent mice. This finding indicates that huSEAP clearance is attributed to an immune-mediated mechanism, which is consistant with previous observations showing that plasma huSEAP level is in inverse proportion to anti-huSEAP antibody titre (5, 7, 8) . Quantitative real-time PCR analysis suggested that the avoidance of immune-activation by the AP-1-mediated supercharging promoter was achieved by lower mRNA expression shortly after DNA delivery in the regional lymph nodes where antigen presentation takes place. Physiologically, AP-1 regulates gene expression in response to a variety of physiological and pathological stimuli, including cytokines, growth factors, stress signals, infections, and chemical and physical stimuli (23) . It is also a general understanding that the role of AP-1 depends upon the cell lineage, differentiation stage, and cellular microenvironment (35) . Further study is necessary to clarify whether this approach causes potential adverse reactions such as mutagenesis and tumor.
The TF-supercharging promoter system that consists of CMV-KKK and RelA failed to ameliorate transgene expression in vivo while it demonstrated a good performance in vitro. The physiological role of RelA might account for the different performance seen in vitro and in vivo. Since RelA is a key transcription factor in initiating host defense against infection (22, 36) , coexpression of RelA and SEAP in animals might activate the immune system and raise immune responses to SEAP. Previous studies have shown that myocytes expressing a foreign gene are subject to attack by inflammatory cells (8, 9) , and transgene expression is mainly impaired by immunemediated mechanisms (5, 7, 8) . Thus, RelA is likely to facilitate immune-mediated elimination of cells bearing huSEAP.
There have been a few reports describing the strategies for transcriptional amplification using recombinant transcription factors (37) (38) (39) (40) . Among these approaches, the fusion protein of yeast GAL4 and the herpes simplex virus type 1 VP16 (GAL4-VP16) (41) is preferentially used (37) (38) (39) , as it can elicit a robust transcriptional activity on a GAL4-responsive promoter. However, none of these studies showed sustained transgene expression by the GAL4-VP16-mediated transcription activation system. Therefore our findings represent the first demonstration that the recombinant TF-mediated transcriptional regulation system succeeded in increasing the longevity, but not magnitude of transgene expression. The present study may open a new avenue for manipulating the regulation of transgene expression. The strategy taken in this study might confer a considerable benefit for gene therapy targeting congenital protein deficiencies in which the therapeutic gene is recognized as foreign by the patient's immune system.
